Sodium zirconium cyclosilicate oral powder
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Oral formulations of sodium zirconium cyclosilicate.
Drugs List
Therapeutic Indications
Uses
Hyperkalaemia
Dosage
Adults
Correction phase
10g three times daily until normokalaemia is achieved (typically within 24 to 48 hours).
If normokalaemia is not achieved after 72 hours of treatment, consider other treatment options.
Maintenance phase
Initially 5g once daily, with possible titration up to 10g once daily, or down to 5g once every other day.
The maximum maintenance dose is 10g once daily.
Patients on chronic haemodialysis
Dose only on non-dialysis days. Initially 5g once daily. Titrate the dose up or down weekly in increments of 5g up to 15g once daily in order to achieve normokalaemia. Titration should be based on the pre-dialysis serum potassium value after the long inter dialytic interval.
Administration
Empty the full contents of the sachet into around 45ml of water and stir well. The powder will not dissolve. The oral suspension should be drunk while still cloudy and if the powder settles should be stirred again to ensure all the contents are taken.
Contraindications
Children under 18 years
Pregnancy
Precautions and Warnings
Restricted sodium intake
Haemodialysis
Contains more than 1 mmol (23 mg) sodium per dose
Advise patient not to take other medicines within 2 hours
Advise patient to report signs of gastrointestinal perforation immediately
Monitor serum potassium regularly
May affect X-ray images
Discontinue if severe hypokalaemia occurs
Limited experience exists in patients with serum potassium concentrations greater than 6.5mmol/L.
Sodium zirconium cyclosilicate may be opaque to X-rays.
Monitor serum potassium after dose titration and after changes are made to products that affect the serum potassium concentration (e.g. diuretics and renin-angiotensin-aldosterone system inhibitors). Once normokalaemia is established, potassium should be monitored regularly.
Long term treatment (more than 1 year) has not been studied.
Sodium zirconium cyclosilicate oral powder contains approximately 400mg sodium per 5g dose.
Pregnancy and Lactation
Pregnancy
Sodium zirconium cyclosilicate is contraindicated during pregnancy.
The manufacturer recommends that it is preferable to avoid the use of sodium zirconium cyclosilicate during pregnancy. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. At the time of writing there is no human data available. Risks are unknown.
Lactation
Sodium zirconium cyclosilicate is considered safe to use during breastfeeding.
The manufacturer advises that sodium zirconium cyclosilicate may be used during breastfeeding. The presence of sodium zirconium cyclosilicate in human milk is unknown but due to its physicochemical properties, sodium zirconium cyclosilicate is not systemically absorbed and is not expected to be excreted in breast milk.
Side Effects
Abdominal distension
Abdominal pain
Constipation
Diarrhoea
Fluid overload
Fluid retention
Generalised oedema
Hypersensitivity reactions
Hypervolaemia
Hypokalaemia
Nausea
Peripheral oedema
Pruritus
Rash
Vomiting
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: June 2020
Reference Sources
Summary of Product Characteristics: Lokelma 5g powder for oral suspension. AstraZeneca UK Limited Ltd. Revised April 2020.
Summary of Product Characteristics: Lokelma 10g powder for oral suspension. AstraZeneca UK Limited Ltd. Revised April 2020.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 18 June 2020
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.